This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Phibro Animal Solid on Global Prospects, Currency Woes Ail
by Zacks Equity Research
Phibro Animal (PAHC) has been gaining from strong volume growth in foreign markets. However, adverse currency movements remain a concern.
3 Cloud Stocks to Buy Right Now
by Benjamin Rains
"The Cloud" has evolved from a budding innovation in tech to one of the largest factors driving growth in the technology sector in only a few years. So check out these three Zacks buy-ranked cloud stocks to consider right now.
Henry Schein's New Buyout to Boost Dental Technology Business
by Zacks Equity Research
Henry Schein (HSIC) expects the acquisition to be neutral to its 2019 earnings per diluted share and accretive thereafter.
Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
by Zacks Equity Research
Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.
Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4
by Zacks Equity Research
Veeva Systems' (VEEV) broad spectrum of products include Veeva Vault, Veeva CRM, Veeva Network and Veeva OpenData.
Zimmer Biomet Solid on Global Prospects Despite Price Pressure
by Zacks Equity Research
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.
Myriad's myPath Melanoma Test Awarded Medicare Coverage
by Zacks Equity Research
The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.
Intuitive Surgical da Vinci SP Gets FDA Nod, Prospects Bright
by Zacks Equity Research
Intuitive Surgical (ISRG) fortifies its foothold in the global robotic-surgery market.
Align Technology (ALGN) Partners With Digital Smile Design
by Zacks Equity Research
Align Technology (ALGN) will be integrating Digital Smile Design's methodology in functional and aesthetic dentistry with its end-to-end digital workflow covering iTero scanners and Invisalign system.
Boston Scientific's WATCHMAN FLX LAAC Device Gets CE Mark
by Zacks Equity Research
Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.
HOLX vs VAR: Which MedTech Stock is a Better Investment Pick?
by Zacks Equity Research
Hologic (HOLX) looks stronger than Varian Medical (VAR) when it comes to current-year earnings projections as well as fundamentals.
QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test
by Zacks Equity Research
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) is currently focusing on improving clinical quality.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Bio-Rad (BIO) seeing solid revenue growth in geographies like Americas and Asia Pacific buoys optimism.
HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick?
by Zacks Equity Research
DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.
Is Veeva Systems (VEEV) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?
Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.
Veeva Systems (VEEV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed at $118 in the latest trading session, marking a -1.99% move from the prior day.
Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?
by Zacks Equity Research
Focus on cloud-based services is likely to boost Veeva Systems' (VEEV) fiscal Q4 results.
Has Veeva Systems (VEEV) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?
Veeva Systems (VEEV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $118.95, marking a +0.24% move from the previous day.
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $116.55, marking a +0.56% move from the previous day.
Veeva Systems (VEEV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed at $109.06 in the latest trading session, marking a +0.62% move from the prior day.
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets bode well for Tandem Diabetes (TNDM).
Veeva Systems (VEEV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $105.49, moving +1.78% from the previous trading session.